Ferritin Nanoparticle Conjugates for Self-Adjuvanting Vaccine Delivery
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current vaccines rely on outdated technologies that pose safety concerns and induce short-lived, weak immune responses, requiring multiple doses, and existing applications of genetic and biochemical engineering in vaccinology have not been fully realized for improving vaccine efficacy.
Innovation Solution
Development of self-adjuvanting ferritin nanoparticles by conjugating immune-stimulatory moieties to ferritin via surface-exposed amino acids or linkers, allowing for targeted co-delivery of antigens and immune-stimulatory molecules in a single macromolecular entity, enhancing immune response and reducing systemic toxicity and dose requirements.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If traditional vaccines use separate antigen and adjuvant molecules, then immune stimulation can be achieved, but systemic toxicity increases and manufacturing complexity increases
Solution Approach 1:
The patent combines antigens and adjuvants into a single ferritin nanoparticle conjugate, where multiple antigenic peptides and immune-stimulatory moieties are co-conjugated to the ferritin surface. This merging eliminates the need for separate administration of antigen and adjuvant, reducing systemic toxicity while maintaining immune response efficacy through localized co-delivery at the injection site.
Solution Approach 2:
Ferritin serves as an intermediary carrier that simultaneously binds both antigenic peptides and adjuvant moieties through its surface-exposed cysteine residues. This intermediary structure enables controlled co-delivery and reduces the harmful effects of free adjuvant circulating systemically, while still providing effective immune stimulation.
2Reliability
If multiple doses are administered to achieve strong immune response, then immunity can be established, but treatment time and manufacturing costs increase
Solution Approach 1:
By merging antigen and adjuvant into a single conjugate delivered in one dose, the patent achieves both priming and boosting immune effects simultaneously. The ferritin nanoparticle structure with multivalent display of antigens and adjuvants creates a potent immunogenic complex that elicits strong and durable immune responses without requiring multiple separate administrations.
Solution Approach 2:
The patent changes the dosage parameter from multiple low-dose administrations to a single high-dose conjugate administration. The ferritin-conjugated antigen-adjuvant complex delivers a concentrated immunogenic payload in one injection, achieving equivalent or superior immune protection compared to multiple traditional vaccine doses.
3Productivity
If traditional vaccine technologies are used, then vaccine production can be maintained, but safety concerns arise and immune response duration is limited
Solution Approach 1:
The patent uses ferritin, a naturally occurring composite protein structure, as the vaccine carrier. Ferritin's hollow spherical structure with multiple subunits provides both structural integrity for manufacturing and inherent biocompatibility for safety. The composite nature of ferritin-conjugated antigen-adjuvant complexes enables scalable production while improving safety profiles compared to traditional whole-pathogen or cell-based vaccines.
Solution Approach 2:
The patent extracts only the essential immunogenic components (specific antigenic peptides and adjuvant moieties) and presents them on the ferritin surface, eliminating unnecessary pathogen components that could cause safety issues. This extracted and purified approach maintains manufacturability while improving safety by removing harmful elements.
4Reliability
If high doses of vaccine are administered to ensure immune response, then immunity can be achieved, but manufacturing burden and costs increase
Solution Approach 1:
By merging antigen and adjuvant into a single conjugate, the patent achieves synergistic immune stimulation that allows lower total doses to elicit equivalent or superior immune responses compared to traditional separate administrations. The ferritin nanoparticle acts as a signal amplifier, where the combined presence of multiple antigens and adjuvants on one particle creates enhanced immunogenicity per unit dose.
Solution Approach 2:
Ferritin serves multiple functions simultaneously: it acts as the antigen carrier, the adjuvant delivery vehicle, and the structural scaffold for multivalent display. This multi-functionality reduces the overall quantity of vaccine material needed compared to traditional approaches where antigen and adjuvant are separate entities requiring separate optimization and administration.
Data Source
AI summary
Ferritin proteins comprising a mutation replacing a surface-exposed amino acid with a cysteine, an N- or C-terminal linker comprising a cysteine, and/or one or more immune-stimulatory moieties linked to the ferritin protein via a surface-exposed amino acid are disclosed. The ferritin proteins can further comprise a non-ferritin polypeptide and be antigenic, e.g., for use in eliciting antibodies against the non-ferritin polypeptide.